BIG PHARMA Raises Cancer Drug Prices By 1400%, Forces Out Natural Remedies
many people will be unable to pay for cancer drugs
Big Pharma has raised cancer drug prices by a massive 1400% while forcing out natural remedies.
As physicians make considerable leaps in terms of treatment, many people will be unable to pay for it due to the greed of the pharmaceutical industry.
One example is the Cancer drugs, Lomustine, which has been taken by patients at home for over 40 years.
In 2012 the drug was just $50, but since the rights were bought by NextSource Biotechnology in 2013, its risen to an astronomical $768 thanks to Big Pharma.
Worked reports: That’s a 1,400% spike. Talking with The Independent, Duke University neuro-oncologist Henry Friedman specified:
“this is simply cost gouging. People are not going to be able to afford it, or they’re going to pay a great deal of cash and have monetary liability.”
It’s not just cancer drugs that have seen an absurd price walking either; in 2017, West-Ward Pharmaceuticals raised the rate of 6 medications utilized to deal with whatever from inflammation to diarrhea, cardiac arrest and bipolar disorder.
The prices of Big Pharma drugs all climbed up in between 75% and 430%
What makes this all the more troubling is the FDA’s persistence on squashing companies that intend to offer natural cancer treatments.
Last year, CNN reported that the FDA sent out cautioning letters to 14 companies who promote their products as able to deal with cancer in some way or another.
At the time, FDA Office of Enforcement director Douglas W. Stearn claimed that the clampdown was performed, in part, since such products may prevent people from seeking more “proper” treatment.
Following that clampdown, the FDA sent four letters to companies promoting marijuana-based products as having the capability to deal with cancer.
The argument was the same old story; such business is being vicious towards cancer clients and ought to for that reason be pinched.
No word yet on if or when FDA will use that same logic to clamp down on drug business that unjustly raises the rates of so-called “appropriate” medications.